|Bid||46.28 x 1300|
|Ask||47.90 x 800|
|Day's range||46.61 - 47.37|
|52-week range||42.29 - 59.00|
|Beta (5Y monthly)||0.24|
|PE ratio (TTM)||24.58|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.
Quest Diagnostics' (DGX) new collaboration with SAHRC will help improve the health and quality of lives of underserved communities.